Page last updated: 2024-09-04

8-chloroadenosine-3',5'-cyclic monophosphorothioate and 1,3-dipropyl-8-cyclopentylxanthine

8-chloroadenosine-3',5'-cyclic monophosphorothioate has been researched along with 1,3-dipropyl-8-cyclopentylxanthine in 1 studies

Compound Research Comparison

Studies
(8-chloroadenosine-3',5'-cyclic monophosphorothioate)
Trials
(8-chloroadenosine-3',5'-cyclic monophosphorothioate)
Recent Studies (post-2010)
(8-chloroadenosine-3',5'-cyclic monophosphorothioate)
Studies
(1,3-dipropyl-8-cyclopentylxanthine)
Trials
(1,3-dipropyl-8-cyclopentylxanthine)
Recent Studies (post-2010) (1,3-dipropyl-8-cyclopentylxanthine)
17011,3011165

Protein Interaction Comparison

ProteinTaxonomy8-chloroadenosine-3',5'-cyclic monophosphorothioate (IC50)1,3-dipropyl-8-cyclopentylxanthine (IC50)
Adenosine receptor A1Rattus norvegicus (Norway rat)0.0051
Adenosine receptor A3Rattus norvegicus (Norway rat)0.0038
Adenosine receptor A2aHomo sapiens (human)0.2033
Adenosine receptor A2bHomo sapiens (human)0.0234
Adenosine receptor A1Homo sapiens (human)0.0083

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Christie, MJ; Hack, SP; Vaughan, CW1

Other Studies

1 other study(ies) available for 8-chloroadenosine-3',5'-cyclic monophosphorothioate and 1,3-dipropyl-8-cyclopentylxanthine

ArticleYear
Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro.
    Neuropharmacology, 2003, Volume: 45, Issue:5

    Topics: Action Potentials; Adenosine; Affinity Labels; Animals; Colforsin; Cyclic AMP; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Enkephalins; Enzyme Inhibitors; gamma-Aminobutyric Acid; In Vitro Techniques; Isoquinolines; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Narcotics; Neural Inhibition; Neurons; Patch-Clamp Techniques; Periaqueductal Gray; Probenecid; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Substance Withdrawal Syndrome; Sulfonamides; Synaptic Transmission; Thioinosine; Time Factors; Uricosuric Agents; Vasodilator Agents; Xanthines

2003